Short answer
Aclaris Therapeutics, Inc. (ACRS) filed an 8-K current report with the SEC on March 10, 2026 reporting Item 7.01 (Regulation FD Disclosure). Reg FD filing signed by CFO Kevin Balthaser on March 9, 2026: substantive disclosure content contained in referenced exhibit.
Aclaris Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Reg FD filing signed by CFO Kevin Balthaser on March 9, 2026: substantive disclosure content contained in referenced exhibit
- Boilerplate liability disclaimer indicates this disclosure is not incorporated by reference into other SEC filings unless explicitly stated
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aclaris Therapeutics, Inc. 8-K filings
Get the next ACRS 8-K as it lands
Follow ACRS for push alerts, or ask the research agent what this filing means.